Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk (NVO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock

Novo Nordisk (NYSE:NVO) has raised its full-year outlook based on a strong first half of 2023 driven by continued high demand for its popular weight-loss drug Wegovy. The Denmark-headquartered global pharmaceutical company expects its sales for 2023 to be up 27% to 33% from the last year, from its prior guidance range of 24% to 30%.

Novo Nordisk raises full-year outlook as Wegovy sales skyrocketed in 2Q

Novo Nordisk raised its outlook as revenue from its popular weight-loss treatment, Wegovy, skyrocketed.

Novo Nordisk Boosts Guidance as Sales of Weight-Loss Drug Wegovy Soar

Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.

Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up

Inversago's drugs use a different approach than most treatments in the obesity and diabetes space.

Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion

Novo Nordisk A/S (NVO) Q2 2023 Earnings Conference Call August 10, 2023 7:00 AM ET Company Participants Daniel Bohsen - CVP & Head, IR Lars Jorgensen - President & CEO Camilla Sylvest - EVP, Commercial Strategy & Corporate Affairs Douglas Langa - EVP, North America Operations Martin Lange - EVP, Development Karsten Knudsen - EVP & CFO Conference Call Participants Martin Parkhoi - SEB Richard Parkes - BNP Paribas Exane Emily Field - Barclays Bank Peter Verdult - Citigroup Harry Sephton - Crédit Suisse Peter Welford - Jefferies Sachin Jain - Bank of America Merrill Lynch Richard Vosser - JPMorgan Chase & Co. Kerry Holford - Berenberg Michael Novod - Nordea Markets Michael Leuchten - UBS Florent Cespedes - Societe Generale Michael Nedelcovych - TD Cowen Simon Baker - Redburn Operator Good day, and thank you for standing by. Welcome to the Q2 2023 Novo Nordisk A/S Earnings Conference Call.

Novo Nordisk A/S (NVO) Q2 2023 Earnings Call Transcript

Novo Nordisk stock fell early Thursday after the company reported $8 billion in sales, missing more bullish expectations.

Novo Nordisk Skids As Massive Sales Growth Misses Even More Bullish Forecasts

Novo Nordisk hopes to show additional health benefits from taking its hugely popular drug Wegovy, apart from losing weight and cutting the risk of heart disease, its drug development executive told Reuters on Thursday.

Novo eyes other health benefits from weight-loss drug Wegovy after major trial

Novo Nordisk expects new data showing the heart benefits of its weight-loss drug Wegovy will help its discussions with public health authorities and other payers about the benefits of paying for it, executives said on Thursday.

Novo Nordisk: weight-loss Wegovy drug's heart benefits will help discussions with payers

Bagsværd, Denmark and Montreal, Canada, 1 0 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.

Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases

Novo Nordisk's limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will likely last into next year, CEO Lars Fruergaard Jorgensen told Reuters on Thursday.

Novo Nordisk's limits on Wegovy US supply seen into 2024, CEO says

Danish drug maker Novo Nordisk said on Thursday it would acquire Canadian company Inversago Pharma in a $1.07 billion deal including the development of an appetite regulator.

Novo Nordisk to acquire obesity drug developer Inversago

Novo Nordisk, the Danish drugmaker that's now the second-largest company in Europe by market capitalization, on Thursday reported a 46% rise in profit and lifted its outlook for the year.

Novo Nordisk, now Europe's second-largest company by market cap, lifts outlook after 46% profit rise

The Danish company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injections Wegovy and Ozempic.

Wegovy-maker Novo Nordisk sales soar 30% on strong demand for its weight-loss drug

Danish drugmaker Novo Nordisk on Thursday hiked its full-year profit and sales forecast for a second time as its weight-loss and diabetes drugs flew off the shelves in the United States.

Novo Nordisk hikes FY outlook as demand for weight-loss drug Wegovy soars

Operating profit increased by 30% in Danish kroner and by 32% at constant exchange rates (CER) to DKK 48.9 billion.

Novo Nordisk's sales increased by 29% in Danish kroner and by 30% at constant exchange rates to DKK 107.7 billion in the first six months of 2023

Weight-loss drugs are the pharmaceutical industry's equivalent of AI, in the sense of being a product with the capability to send shares soaring. Novo Nordisk A/S NYSE: NVO, maker of Wegovy, saw its stock gap up more than 16% on August 8, after the weight-loss medication demonstrated a noteworthy reduction in the risk of cardiovascular events for overweight adults.

Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results

Eli Lilly

Pfizer

Boston Beer Company

Constellation Brands

Molson Coors Brewing

If weight-loss drugs become multibillion-dollar blockbusters, snack makers and beer companies could take a hit, analysts say.

For Dieters, Obesity Drugs Are a Magic Pill. These Stocks Could Lose.

Weight loss injections can lower the risk of a heart attack or stroke in obese people with cardiovascular disease by a fifth, a new study has suggested.

Weight loss injections 'can lower heart attack and stroke risk by a fifth'

Novo Nordisk said the results of a late-stage drug trial showed weight loss drug Wegovy also can cut the risk of heart disease in certain patients.

Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial shows

Shares of Eli Lilly and Novo Nordisk both soared to record highs on Tuesday, as sales increased of Eli Lilly's Mounjaro and as Novo Nordisk reports a promising clinical trial of its drug Wegovy.

Weight-Loss Drug Frenzy Drives Eli Lilly And Novo Nordisk Stock To Record Highs

The European drugmaker's stock is rallying Tuesday after a study showed its popular weight loss pill Wegovy could lower risks of heart attack and stroke. On Tuesday, European company Novo Nordisk's shares hit record highs.

Why is Novo Nordisk's stock up? Here's what to know about its weight loss drug Wegovy's heart disease trials

ADRs of Novo Nordisk surged to an all-time high after a study found Novo Nordisk's Wegovy weight-loss drug also helped cut risk of major adverse cardiovascular events by 20%.

Novo Nordisk ADRs Surge After Wegovy Shown to Reduce Heart Attack, Stroke Risks

The trial showed that patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo, Novo said.

Novo weight-loss drug Wegovy shows heart benefit in trial

A new class of weight loss drugs are powering massive stock market gains for Novo Nordisk and Eli Lilly. Both stocks surged more than 16% on Tuesday, boosting the combined valuation of both companies to nearly $1 trillion.

News for Novo Nordisk Stock (NVO)